Experimental Immunology

J THOMAS1, Y LING1, S KRISHNAN2, D FERENS2, B KEMP-HARPER2, C SOBEY1, G DRUMMOND1, B HUUSKES1, A VINH1 1Department of Physiology, Anatomy and Microbiology, La Trobe University, Bundoora, Australia, 2Department of Pharmacology, Monash University, Clayton, Australia Aim: To test the...
  • June 14, 2018
Read More
P PURI1, G WALTERS1,3, K GIBSON1, A COOK2, D FULCHER3, C VINUESA2,3, SJIANG1,2,3 1The Canberra Hospital , Canberra City., Australia, 2Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Canberra City , Australia, 3Centre for Personalised Immunology,...
  • June 14, 2018
Read More
S JIANG1,2,3, V ATHANASOPOULOS1,2, J ELLYARD1,2, A CHUAH4, J CAPPELLO1,2, S PRABHU1, J CARDENAS5, J GU5, J ROCO1,2, I PAPA1,2, M YABAS1, G WALTERS1,2,3, G BURGIO1, K  MCKEON1,2, A ENDERS1,2, P CANETE1,2, S  ALEXANDER2,6, A KITCHING2,7, N SHEN8, J BABON9,...
  • June 13, 2018
Read More
G TESCH1,2, E OZOLS1, M YOUNG3, D NIKOLIC-PATERSON1,2 1Monash Health, Clayton, Australia, 2Monash University Centre for Inflammatory Diseases, Clayton, Australia, 3Hudson Institute of Medical Research, Clayton, Australia Aim: To evaluate whether macrophage mineralocorticoid receptor signaling contributes to the development of...
  • June 5, 2018
Read More
HG HEALY1,2,3, B LAW1,2,4,  X WANG1,2, K KILDEY1,2,  K GIULIANI1,2,  K BEAGLEY4, R WILKINSON1,2,3,4, A KASSIANOS1,2,3,4 1Pathology Queensland, Brisbane, Australia, 2Royal Brisbane and Women’s Hospital, Brisbane, Australia, 3University of Queensland, Brisbane, Australia, 4Queensland University of Technology, Brisbane, Australia Aim: To...
  • June 5, 2018
Read More
F MA1,2, J LIU1,2, E OZOLS1,2,  PCHEW1,2, J HO1,2, Y HAN1,2, K BLEASE3, B BENNETT3, G TESCH1,2, D NIKOLIC-PATERSON1,2 1Dept of Nephrology, Monash Medical Centre, Clayton, Australia, 2Monash University Centre for Inflammatory Diseases, Clayton, Australia, 3Celgene, San Diego, USA Aim:...
  • June 5, 2018
Read More
J DICK1, P GAN1, M ALIKHAN1, R KITCHING1, S HOLDSWORTH1 1Monash University , Clayton , Australia Aim: To determine the potential of low dose IL-2 therapy in experimental ANCA-associated vasculitis (AAV). Background: Low dose IL-2 expands regulatory T cells (Tregs) and is...
  • June 5, 2018
Read More
G TESCH1,2,  N PULLEN3, D NIKOLIC-PATERSON1,2 1Monash Health, Australia, 2Monash University Centre for Inflammatory Diseases, Clayton, Australia, 3Pfizer Worldwide Research & Development, Cambridge, USA Aim: To evaluate intervention with a CCR2 antagonist (CCR2A) in a model of progressive diabetic glomerulosclerosis...
  • June 5, 2018
Read More
Recent Comments
    Categories